56 percent return on cuv?

If Stanton's pps target is post-EPP aproval, then he's talking about a 56% return on investment henceforward.

For most investments, a 56% return is outstanding. But, when you're talking about the risks of regulatory approval decisions (risky for ANY pharma / biotech stock), a 56% return on a first in-class drug is not as great of a risk/ reward profile to me as it would appear at first glance.

For other biotechs that I have seen, there is much bigger upside potential for post-approval.

Having said that, I feel this drug will be approved (I've always said that) and that there is less risk than most other first in-class drug applications out there.

Also, Stanton's call is not gospel.

But there are biotechs out there that perform better than 56% 6-9 months outside of approval.

Remember, we're competiting with other pharma / biotech investments given investors in this space are looking for the best investment opportunities out there for their money.